Minerva Pharma Consulting: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Minerva Pharma Consulting
Largest movements
- Cash +€92,338
up €92,338 (+59.9%), from €154,048 to €246,386
mainly Other debts (+€215,747) and Net result for the year (+€97,985)
- Receivables within one year +€6,435
up €6,435 (+59.0%), from €10,915 to €17,350
of which Trade receivables: +€6,593
- Other debts +€215,747
up €215,747 (+35,880%), from €601 to €216,349
- Reserves -€156,543
down €156,543 (-100%), from €156,543 to €0
- Tax, wage and social debts +€40,571
up €40,571 (+406%), from €9,995 to €50,567
- Gross operating margin +€21,984
up €21,984 (+20.8%), from €105,487 to €127,471
- Taxes +€5,286
up €5,286 (+24.1%), from €21,954 to €27,240
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €172,790 | €272,138 | +€99,348 | +57.5% |
| Fixed assets | 21/28 | €4,254 | €5,672 | +€1,419 | +33.3% |
| Tangible fixed assets | 22/27 | €4,254 | €5,672 | +€1,419 | +33.3% |
| Furniture and vehicles | 24 | - | €1,926 | +€1,926 | |
| Other tangible fixed assets | 26 | €4,254 | €3,746 | -€508 | -11.9% |
| Current assets | 29/58 | €168,536 | €266,466 | +€97,929 | +58.1% |
| Amounts receivable within one year | 40/41 | €10,915 | €17,350 | +€6,435 | +59.0% |
| Trade receivables | 40 | €9,500 | €16,093 | +€6,593 | +69.4% |
| Other amounts receivable | 41 | €1,415 | €1,257 | -€158 | -11.2% |
| Cash at bank and in hand | 54/58 | €154,048 | €246,386 | +€92,338 | +59.9% |
| Deferred charges and accrued income | 490/1 | €3,572 | €2,729 | -€843 | -23.6% |
| Total equity and liabilities | 10/49 | €172,790 | €272,138 | +€99,348 | +57.5% |
| Equity | 10/15 | €159,543 | €3,000 | -€156,543 | -98.1% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Reserves | 13 | €156,543 | €0 | -€156,543 | -100% |
| Distributable reserves | 133 | €156,543 | €0 | -€156,543 | -100% |
| Profit (loss) carried forward | 14 | €0 | €0 | = | |
| Amounts payable | 17/49 | €13,247 | €269,138 | +€255,891 | +1,932% |
| Amounts payable within one year | 42/48 | €13,247 | €269,138 | +€255,891 | +1,932% |
| Trade debts | 44 | €2,650 | €2,223 | -€427 | -16.1% |
| Suppliers | 440/4 | €2,650 | €2,223 | -€427 | -16.1% |
| Taxes, remuneration and social security | 45 | €9,995 | €50,567 | +€40,571 | +406% |
| Taxes | 450/3 | €9,995 | €50,567 | +€40,571 | +406% |
| Other amounts payable | 47/48 | €601 | €216,349 | +€215,747 | +35,880% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €508 | €823 | +€315 | +62.1% |
| Other operating charges | 640/8 | €391 | €63 | -€328 | -83.8% |
| Gross operating margin | 9900 | €105,487 | €127,471 | +€21,984 | +20.8% |
| Operating profit (loss) | 9901 | €104,588 | €126,584 | +€21,996 | +21.0% |
| Financial income | 75/76B | €25 | €285 | +€260 | +1,023% |
| Recurring financial income | 75 | €25 | €285 | +€260 | +1,023% |
| Financial charges | 65/66B | €2,100 | €1,644 | -€456 | -21.7% |
| Recurring financial charges | 65 | €2,100 | €1,644 | -€456 | -21.7% |
| Profit (loss) for the period before taxes | 9903 | €102,513 | €125,225 | +€22,712 | +22.2% |
| Income taxes | 67/77 | €21,954 | €27,240 | +€5,286 | +24.1% |
| Profit (loss) for the period | 9904 | €80,559 | €97,985 | +€17,426 | +21.6% |
| Profit (loss) for the period to be appropriated | 9905 | €80,559 | €97,985 | +€17,426 | +21.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 October 2026 via checked.be.